Optimized Cytogenetic Risk-Group Stratification of KMT2A-Rearranged Pediatric Acute Myeloid Leukemia.

Fecha de publicación: 15/04/2024 Fecha Ahead of Print: 15/04/2024

Autores de IIS La Fe

• José María Fernández Navarro

  Autor

Participantes ajenos a IIS La Fe

• van Weelderen, Romy E.
• Harrison, Christine J.
• Klein, Kim
• Jiang, Yilin
• Abrahamsson, Jonas
• Alonzo, Todd
• Aplenc, Richard
• Arad-Cohen, Nira
• Bart-Delabesse, Emmanuelle
• Buldini, Barbara
• De Moerloose, Barbara
• Dworzak, Michael N.
• Elitzur, Sarah
• Gamis, Alan
• Gerbing, Robert B.
• Goemans, Bianca F.
• de Groot-Kruseman, Hester A
• Guest, Erin
• Ha, Shau-Yin
• Hasle, Henrik
• Kelaidi, Charikleia
• Lapillonne, Helene
• Leverger, Guy
• Locatelli, Franco
• Miyamura, Takako
• Noren-Nystrom, Ulrika
• Polychronopoulou, Sophia
• Rasche, Mareike
• Rubnitz, Jeffrey E.
• Stary, Jan
• Tierens, Anne
• Tomizawa, Daisuke
• Zwaan, C. Michel
• Kaspers, Gertjan J. L.

Grupos

• Investigación Clínica y Traslacional en Cáncer

  

  Leader

  José Gómez Codina

Abstract

Comprehensive international consensus on cytogenetic risk-group stratification of KMT2A-rearranged (KMT2A-r) pediatric acute myeloid leukemia (AML) is lacking. This retrospective (2005-2016) International Berlin-Frankfurt-Munster Study Group study on 1,256 children with KMT2A-r AML aimed to validate the prognostic value of established recurring KMT2A fusions and additional cytogenetic aberrations (ACAs), and secondly, to define additional, recurring KMT2A fusions and ACAs, evaluating their prognostic relevance. Compared to our previous study, three additional, recurring KMT2A-r groups were defined: Xq24/KMT2A::SEPT6, 1p32/KMT2A::EPS15, 17q12/t(11;17)(q23;q12). Across 13 KMT2A-r groups, 5-year event-free survival probabilities varied significantly (21.8% to 76.2%; P<0.01). ACAs occurred in 46.8% of 1,200 patients with complete karyotypes, correlating with inferior overall survival (56.8% vs 67.9%; P<0.01). Multivariable analyses confirmed independent associations of 4q21/KMT2A::AFF1, 6q27/KMT2A::AFDN, 10p12/KMT2A::MLLT10, 10p11.2/KMT2A::ABI1, and 19p13.3/KMT2A::MLLT1 with adverse outcomes, but not those of 1q21/KMT2A::MLLT11 and trisomy 19 with favorable and adverse outcomes, respectively. Newly identified ACAs with independent adverse prognoses were monosomy 10, trisomies 1, 6, 16, and X, add(12p), and del(9q). Among patients with 9p22/KMT2A::MLLT3, the independent association of French-American-British-type M5 with favorable outcome was confirmed, and those of trisomy 6 and measurable residual disease at end of induction with adverse outcomes were identified. We provide evidence to incorporate the five adverse-risk KMT2A fusions into the cytogenetic risk-group stratification of KMT2A-r pediatric AML, to revise the favorable-risk classification of 1q21/KMT2A::MLLT11 to intermediate risk, and to refine risk-stratification of 9p22/KMT2A::MLLT3 AML. Future studies should validate the associations between the newly identified ACAs and outcome, and unravel the underlying biological pathogenesis of KMT2A fusions and ACAs.

Copyright © 2024 American Society of Hematology.

Keywords

• CHILDHOOD; CHILDREN; CHEMOTHERAPY; ADOLESCENTS; TRIAL; EXPRESSION; SURVIVAL; RELAPSE